EGFR and colorectal carcinoma: The first explanation for primary resistance to anti-EGFR drugs can be the presence of mutations in RAS genes [29,30], which are found to be mutated in nearly half of patients with CRC (36% for KRAS and 10% for NRAS, respectively) [31] (Figure 2).